Imatinib mesylate-related fatal acute hepatic failure in a patient with chronic myeloid leukaemia and chronic hepatitis B infection.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Singapore medical journal

• Publication date

  2008-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 18362995
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Herpes zoster complicating imatinib mesylate for gastrointestinal stromal tumour.

  2007cited by this paper
• Imatinib mesylate selectively impairs expansion of memory cytotoxic T cells without affecting the control of primary viral infections.

  2006cited by this paper
• Fatal hepatitis B virus reactivation in a chronic myeloid leukemia patient during imatinib mesylate treatment

  2006cited by this paper
• AASLD position paper: The management of acute liver failure

  2005cited by this paper
• Imatinib (Gleevec)-induced hepatotoxicity.

  2005cited by this paper
• Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro

  2004cited by this paper
• Severe Hepatitis and Complete Molecular Response Caused by Imatinib Mesylate: Possible Association of Its Serum Concentration with Clinical Outcomes

  2004cited by this paper
• Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo.

  2004cited by this paper
• Histological features of acute hepatitis after imatinib mesylate treatment

  2003cited by this paper
• Clinical problem-solving. A window of opportunity.

  2003cited by this paper
• Development of Varicella-Zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate.

  2003cited by this paper
• Imatinib mesylate-induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis

  2002cited by this paper
• Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia.

  2002cited by this paper
• Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

  2002cited by this paper
• Hepatitis viruses under immunosuppressive agents

  1998cited by this paper
• Varicella-zoster virus infection associated with acute liver failure.

  1998cited by this paper
• Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

  1991cited by this paper
• Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

  1991cited by this paper
• Herpes simplex hepatitis in a patient with psoriatic arthritis taking prednisone and methotrexate. Report and review of the literature.

  1991cited by this paper
• Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier.

  1985cited by this paper

• HCV Reactivation in a Patient with Hepatocellular Carcinoma Due to Sorafenib: A Case Report

  2024cites this paper
• The Combination of Gefitinib and Acetaminophen Exacerbates Hepatotoxicity via ROS-Mediated Apoptosis

  2024cites this paper
• The prevalence of hepatic and thyroid toxicity associated with imatinib treatment of chronic myeloid leukaemia: a systematic review

  2023cites this paper
• Imatinib mesylate-induced acute hepatotoxicity

  2023cites this paper
• Viral Infections and Incidence of Reactivations in Chronic Myeloid Leukemia Patients

  2023cites this paper
• CrkII/Abl phosphorylation cascade is critical for NLRC4 inflammasome activity and is blocked by Pseudomonas aeruginosa ExoT

  2022cites this paper
• CrkII/Abl phosphorylation cascade is critical for NLRC4 inflammasome activity and is blocked by Pseudomonas aeruginosa ExoT

  2022cites this paper
• Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies

  2020cites this paper
• Recent advances in understanding the hepatotoxicity associated with protein kinase inhibitors

  2020cites this paper
• An electronic alert system increases screening for hepatitis B and C and improves management of patients with haematological disorders

  2020cites this paper
• Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians.

  2020cites this paper
• Novel Score-based Decision Approach in Chronic Myeloid Leukemia Patients After Acute Toxic Imatinib-induced Liver Injury

  2019cites this paper
• Evaluation of Hepatitis B Reactivation Among Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase Inhibitors

  2019cites this paper
• Histological changes of the rat liver after administration of imatinib mesylate:an experimental study

  2019cites this paper
• Drugs and Toxins

  2018cites this paper
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors).

  2018cites this paper
• Infections in patients on BCR-ABL tyrosine kinase inhibitor therapy: cases and review of the literature

  2018cites this paper
• Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases

  2018cites this paper
• Chinese consensus on management of tyrosine kinase inhibitor-associated side effects in gastrointestinal stromal tumors

  2018cites this paper
• Imatinib-induced fulminant liver failure in chronic myeloid leukemia: role of liver transplant and second-generation tyrosine kinase inhibitors: a case report

  2018cites this paper
• Prevention of Hepatitis B Arising from Chemotherapy-induced Hepatitis B Virus Reactivation: an Approach by Pharmacists

  2017cites this paper
• Hepatitis B reactivation in patients receiving targeted therapies

  2017cites this paper
• Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.

  2016cites this paper
• Prevention of Hepatitis B reactivation in the setting of immunosuppression

  2016cites this paper
• Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure.

  2015cites this paper
• Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase Inhibitors

  2015cites this paper
• A Newly Diagnosed CML-CP HBV Carrier was Safely Treated with Dasatinib and Entecavir

  2014cites this paper
• Hepatitis B viral reactivation secondary to imatinib treatment in a patient with gastrointestinal stromal tumor.

  2014cites this paper
• Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.

  2013cites this paper
• Hepatitis B virus reactivation in a chronic myeloid leukemia patient treated with imatinib mesylate.

  2012cites this paper
• Gefitinib-Induced Hepatotoxicity in Patients Treated for Non-Small Cell Lung Cancer

  2012cites this paper
• [Survival following liver transplant due to imatinib-induced acute liver failure: a case study].

  2012cites this paper
• 13 – Hepatic injury due to drugs, herbal compounds, chemicals and toxins

  2012cites this paper
• Supervivencia tras trasplante hepático por fallo hepático agudo debido a imatinib: a propósito de un caso

  2012cites this paper
• [Fulminating hepatitis for imatinib in a patient with chronic myeloid leukaemia].

  2011cites this paper
• Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia

  2011cites this paper
• Toksyczne uszkodzenie wątroby w przebiegu leczenia imatynibem chorych z przewlekłą białaczką szpikową Imatinib-induced toxic liver failure in patients with chronic myeloid leukemia

  2010cites this paper
• Histopathological study of the hepatic and renal toxicity associated with the co-administration of imatinib and acetaminophen in a preclinical mouse model.

  2010cites this paper
• Living donor liver transplantation for acute hepatic failure caused by reactivation of hepatitis B virus infection after chemotherapy for hematologic malignancy: case reports.

  2010cites this paper
• Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors

  2010cites this paper
• Drug-induced liver injury: what was new in 2008?

  2009influential citation
• Gastrointestinal toxicities of novel agents in cancer therapy.

  2009cites this paper
• Reduced exposure of imatinib after coadministration with acetaminophen in mice

  2009cites this paper
• Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review

  2009cites this paper